What information do you need to know before using Sotolaxib?

Before using Sotorasib (Sotorasib), patients need to know some key drug information to ensure safe and effective treatment. Sotoracib is a targeted drug targeting the KRAS G12C mutation. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation. It helps slow tumor growth by specifically inhibiting KRAS G12C mutation activity. Since this is a relatively new targeted drug, patients need to understand its indications, usage and possible side effects in detail before use.

Patients need to confirm whether they carryKRAS G12C mutation. Sotoracib is only suitable for patients with lung cancer who are KRAS G12C mutation-positive, so it is important to conduct genetic testing to confirm whether they meet this indication. This drug should not be used in patients who have not had genetic testing or whose test results are inconsistent. Therefore, doctors usually arrange relevant molecular biology tests before prescribing drugs to ensure the pertinence and efficacy of the drugs.

The usage and dosage of sotoraxib also need to be understood. Generally speaking, sotorasiib is usually taken orally once a day, and the dosage is usually 240 mg, but the specific dosage and treatment duration should be adjusted according to the patient's specific condition and the doctor's recommendations. Patients should strictly follow the doctor's instructions when using drugs and avoid changing the dosage or stopping the drug on their own, so as not to affect the therapeutic effect. At the same time, the drug needs to be independent of food and can be taken before or after meals.

Patients should also be aware of the possible side effects of sotoraxib. Common side effects include fatigue, loss of appetite, nausea, diarrhea, and abnormal liver function. More serious side effects, such as liver toxicity, may affect the continued use of the drug. Therefore, liver function and other indicators need to be monitored regularly during use of the drug. If patients experience any discomfort, especially severe liver problems (such as jaundice, abnormal liver enzyme levels, etc.), they should inform their doctor immediately. If necessary, the treatment plan may need to be adjusted or the drug suspended.

Reference materials:https://www.lumakras.com/